News coverage about SeaSpine (NASDAQ:SPNE) has been trending positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. SeaSpine earned a news impact score of 0.26 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 45.8099586093288 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Several research firms have recently weighed in on SPNE. ValuEngine raised SeaSpine from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Zacks Investment Research cut SeaSpine from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Ladenburg Thalmann began coverage on SeaSpine in a research note on Thursday, December 14th. They set a “buy” rating and a $20.00 price objective for the company. BTIG Research reiterated a “buy” rating and issued a $17.00 price target on shares of SeaSpine in a research note on Friday, March 2nd. Finally, HC Wainwright set a $15.00 price target on SeaSpine and gave the company a “buy” rating in a research note on Friday, March 2nd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $17.20.
SPNE stock traded up $0.26 during midday trading on Friday, hitting $10.90. 77,794 shares of the company’s stock were exchanged, compared to its average volume of 55,410. The stock has a market cap of $158.46, a price-to-earnings ratio of -4.22 and a beta of 0.33. SeaSpine has a 1-year low of $7.37 and a 1-year high of $13.46.
SeaSpine (NASDAQ:SPNE) last released its earnings results on Wednesday, February 28th. The medical equipment provider reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.04). SeaSpine had a negative return on equity of 29.96% and a negative net margin of 24.36%. The company had revenue of $33.98 million for the quarter. analysts predict that SeaSpine will post -1.99 EPS for the current fiscal year.
WARNING: “SeaSpine (SPNE) Given Daily News Impact Rating of 0.26” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/08/seaspine-spne-given-daily-news-impact-rating-of-0-26.html.
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine.
Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.